Enfusion, Inc.

ENFN

Market cap $1.02B

BOISE, Idaho & CHICAGO--(BUSINESS WIRE)--Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today announced the preliminary results of the elections made by Enfusion shareholders of record regarding the form of merger consideration (the “Merger Consideration”) they wish to receive in connection with Clearwater's acquisition of Enfusion (the "Transaction"). As previously disclosed, the deadline to have made such an election was 5:00 p.m. Eastern Time on.

BOISE, Idaho & CHICAGO--(BUSINESS WIRE)--Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today announced that the deadline for Enfusion shareholders of record to elect the form of merger consideration (the “Merger Consideration”) they wish to receive in connection with Clearwater's acquisition of Enfusion (the "Transaction") is 5:00 p.m. Eastern Time on April 16, 2025 (such deadline, as it may be extended, the "Election Deadline"). Enfusion sharehol.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics Holdings, Inc. (NYSE: CWAN). Under the terms of the proposed transaction, shareholders of Enfusion will receive $5.85 in cash and $5.40 in Clearwater Class A Common Stock for each share of Enfusion that they own. KSF is seeking to determine whether this consi.

Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.04 per share a year ago.

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Total revenue was $52.9 million, up 13.9% compared to the same period in the prior year. Gross Profit was $36.5 million with a Gross Profit Margin of 69.0%. Adjusted Gross Profit was $3.

BOISE, Idaho--(BUSINESS WIRE)--Clearwater Analytics Holdings, Inc. (NYSE: CWAN) (“Clearwater” or the “Company”), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”), a leader in software-as-a-service solutions for the investment management and hedge fund industry, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR A.

NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock is fair to Enfusion shareholders. Halper Sadeh encourages Enfusion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.

NEW YORK CITY, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.

NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.